Abstract: Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

Abstract: A liposome formulation containing about 1% diclofenac is an effective topical anti-inflammatory topical treatment for lameness in horses. More particularly it has been discovered that a formulation containing vitamin E, phospholipid and diclofenac salt such as the sodium or potassium salt is a highly effective topical anti-inflammatory formulation that is particularly effective in treating lameness in horses.

Abstract: The invention provides methods and compositions for the treatment of lameness, navicular syndrome, osteoarthritis, or combinations thereof in horses.

Abstract: A liposome formulation containing about 1% diclofenac is an effective topical anti-inflammatory topical treatment for lameness in horses. More particularly it has been discovered that a formulation containing vitamin E, phospholipid and diclofenac salt such as the sodium or potassium salt is a highly effective topical anti-inflammatory formulation that is particularly effective in treating lameness in horses.

Abstract: The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds, and methods of their manufacture and use. The pharmaceutical compositions contain microcrystals of pharmacologically active compounds which are encapsulated within a phospholipid layer which contain a unique combination of phospholipids. The pharmaceutical compositions may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 &mgr;m and 3.0 &mgr;m in diameter, at least ten percent of the microcrystals are from 3.0 &mgr;m to 10 &mgr;m in diameter, and the composition may contain microcrystals which are greater than 10 &mgr;m in diameter. Methods of manufacturing the composition are disclosed, as well as various methods of administration.

Abstract: The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds and methods of their manufacture and use. Sustained release times of 10-12 days have been achieved with the present invention. The present invention provides microcrystal compositions. The microcrystals comprise pharmacologically active compounds and are contained within a phospholipid layer which contains a unique combination of phospholipids. The present invention may be applied to a wide range of pharmaceutical compositions which may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 &mgr;m to about 3.0 &mgr;m in diameter, at least ten percent of the microcrystals are from about 3.0 &mgr;m to about 10 &mgr;m in diameter, and the composition contains microcrystals which are greater than 10 &mgr;m in diameter.

Abstract: A method of treating fleas on dogs and cats by orally administering a larvicidally or ovicidally effective amount of flea growth inhibiting benzoylurea.

Abstract: The present invention relates to a method of treating dogs and cats having topically disposed fleas. More particularly, the invention relates to such a method of treatment wherein the dog or cat is dosed with a larvicidally or ovicidally effective amount of flea growth inhibiting substance capable of reaching the flea via the hosts blood.